Monoclonal antibodies and Fc fragments for treating solid tumors

noclonal antibodies and Fc fragments for treating solid tumors Review (3563) Total Article Views Authors: Eisenbeis AM, Grau SJ Published Date January 2012 Volume 2012:6 Pages 13 - 20 DOI: http://dx.doi.org/10.2147/BTT.S19955 Received: 10 October 2011 Accepted: 16 November 2011 Published: 05 January 2012 Andrea M Eisenbeis, Stefan J Grau Department of Neurosurgery, University Hospital of Cologne, Cologne, Germany Abstract: Advances in biotechnology, better understanding of pathophysiological processes, as well as the identification of an increasing number of molecular markers have facilitated the use of monoclonal antibodies and Fc fragments in various fields in medicine. In this context, a rapidly growing number of these substances have also emerged in the field of oncology. This review will summarize the currently approved monoclonal antibodies used for the treatment of solid tumors with a focus on their clinical application, biological background, and currently ongoing trials.